Targeted Therapies and Immunotherapy in Prostate Cancer

In the era of the molecular medicine, new targets are discovered and testing for clinical benefits in prostate carcinoma. Recent clinical and preclinical studies focused on understanding the molecular landscape of castration-resistant prostate cancercastration-resistant prostate cancer (CRPC) to fin...

Full description

Saved in:
Bibliographic Details
Published inPrinciples and Practice of Urooncology pp. 367 - 374
Main Authors Aksoy, Sercan, Şendur, Mehmet Ali Nahit
Format Book Chapter
LanguageEnglish
Published Switzerland Springer International Publishing AG 2017
Springer International Publishing
Subjects
Immunotherapy
Oncology
Prostate cancer
Radiotherapy
Targeted therapies
Urology & urogenital medicine
Online AccessGet full text

Cover

More Information
Summary:In the era of the molecular medicine, new targets are discovered and testing for clinical benefits in prostate carcinoma. Recent clinical and preclinical studies focused on understanding the molecular landscape of castration-resistant prostate cancercastration-resistant prostate cancer (CRPC) to find out the potential therapeutic targets. Androgen pathway is the main study field. And new-generation androgen pathway targeting agents are testing and new molecular targets also defined. Androgen receptor targeting is demonstrated as overall survival benefit in CRPC. AbirateroneAbiraterone and enzalutamideEnzalutamide that targets androgen pathway had survival benefit and had FDA approval in castration-resistant prostate carcinoma (CRPC) patients. Besides the androgen pathway, PARP inhibitors, PI3K/Akt, immune checkpoints, and PD1 and PDL1 inhibitors are drugable targets. This chapter focuses on the targeted therapies and immunotherapies in prostate adenocarcinoma, especially CRPC.
ISBN:9783319561134
3319561138
DOI:10.1007/978-3-319-56114-1_22